Pfizer-BioNTech and Moderna COVID-19 vaccines sit in boxes at Borinquen Health Care Center in Miami on May 29, 2025. Joe Raedle/Getty ImagesModerna Inc. will pay as much as $2.25 billion to end a protracted patent fight with Arbutus Biopharma Corp. and Genevant Sciences GmbH regarding technology deployed in its COVID-19 vaccines, according to an announcement released Tuesday by Arbutus.The settlement includes an upfront payment of $950 million from Moderna to Arbutus and Genevant in the third quarter of 2026. An additional payment of up to $1.3 billion is contingent on the outcome of Moderna’s appeal regarding a federal statute that could limit its liability for patent infringement related to government contracts.
21.1
C
Ottawa
Sunday, August 2, 2026
The Alliance Press is the world leader in online chained news and information and seeks to inform, engage and empower the world. We expose the information that wasn't known before or current events broadcast over the radio, television, online or in print media. Our content is now available through your mobile phone. No matter where your on-the-go lifestyle takes you, TAP brings the news directly to you.
More from CN
Contact
© The Alliance Media Group design by CODEUS